Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease

Metastatic basal cell carcinoma may be treated with hedgehog pathway inhibitors, including vismodegib and sonidegib. However, patients can demonstrate resistance to these agents. We describe a man with metastatic basal cell carcinoma who did not respond well to vismodegib and sonidegib. Next generat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Philip R., Kato, Shumei, Goodman, Aaron M., Ikeda, Sadakatsu, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578053/
https://www.ncbi.nlm.nih.gov/pubmed/28788102
http://dx.doi.org/10.3390/ijms18081663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578053/
https://www.ncbi.nlm.nih.gov/pubmed/28788102
http://dx.doi.org/10.3390/ijms18081663

Ejemplares similares